Phase 3 N=39 Mycophenolate Mofetil in Patients With Progressive Idiopathic Membranous Nephropathy
Glomerulonephritis, Membranous
Primary: Percentage of Complete Remission — 4; 3 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=14 A Study of Belimumab in Idiopathic Membranous Glomerulonephropathy
Glomerulonephritis, Membranous
Primary: Change From Baseline in Proteinuria Levels at Week 28 — 0.7552 Ratio
Phase 4 N=40 Mycophenolate Mofetil and Tacrolimus Versus Tacrolimus for the Treatment of Idiopathic Membranous Glomerulonephritis
Glomerulonephritis, Membranous
Primary: Number of Patient Who Gained Remission From the Nephrotic Syndrome — 8; 8 Participants — p=0.7
Phase 3 N=130 MEmbranous Nephropathy Trial Of Rituximab
Idiopathic Membranous Nephropathy
Primary: Remission Status — 39; 13 Participants — p=0.001
Phase 4 N=60 Acthar for Treatment of Proteinuria in Membranous Nephropathy Patients
Proteinuria · Idiopathic Membranous Nephropathy
Primary: Percentage of Participants With Complete or Partial Remission in Proteinuria at 24 Weeks — 1; 5; 2; 0 Participants
Phase 4 N=5 Adrenocorticotropic Hormone in Membranous Nephropathy
Membranous Nephropathy
Primary: Change in Proteinuria — 4.56; 1.36 ratio
Phase 2 N=31 Trial to Assess Safety and Efficacy of MOR202 in Anti-PLA2R + Membranous Nephropathy (aMN)
Glomerulonephritis, Membranous · antiPLA2R Positive
Primary: Number of Participants With Adverse Events — 15; 12 Participants
Phase 2 N=9 Study to Evaluate the Safety and Efficacy of Filgotinib and Lanraplenib in Adults With Lupus Membranous Nephropathy (LMN)
Lupus Membranous Nephropathy
Primary: Percent Change in Urine Protein From Baseline (Day 1) to Week 16 — -2.8; -51.2 percent change
Phase 2 N=21 Phase II Study Assessing Safety and Efficacy of APL-2 in Glomerulopathies
IgA Nephropathy · Lupus Nephritis · Membranous Nephropathy
Primary: Part A: Change From Baseline in Proteinuria at Week 48 — -0.1364; 0.3560; 0.3430; -2.0347 ratio
Phase 2 N=12 Daratumumab in Treatment of PGNMID and C3 GN
Membranoproliferative Glomerulonephritis
Primary: Number of Treatment-Emergent Adverse Events — 5 Serious Adverse Events
Phase 3 N=144 A Study to Evaluate the Efficacy and Safety of Rituximab in Subjects With International Society of Nephrology/Renal Pathology Society (ISN/RPS) 2003 Class III or IV Lupus Nephritis
Lupus Nephritis
Primary: Percentage of Participants Who Achieved a Complete Renal Response (CRR), a Partial Renal Response (PRR), or no Renal Response (NRR) at Week 52 — 26.4; 30.6; 30.6; 15.3…
Phase 2 N=15 Permeability Factor in Focal Segmental Glomerulosclerosis
Focal Segmental Glomerulosclerosis
Primary: Reduction in Proteinuria in Recurrent FSGS Following Renal Transplant With Plasma Exchange and Cyclophosphamide. — 0; 0; 0.5; 0.25 proportion of participants with…
Phase 2 N=11 Pilot Study of Rituximab to Treat Fibrillary Glomerulonephritis
Fibrillary Glomerulonephritis
Primary: Change in 24 Hour Creatinine Clearance — 41.0 mL/min/SA — p=0.072
Phase 4 N=34 Rituximab in Progressive Immunoglobulin A (IgA) Nephropathy
IgA Nephropathy
Primary: Change in Proteinuria at 12 Months — 3; 3; 1; 2 participants
Phase 2 N=12 Podocyte Retinoids
Collapsing Glomerulopathy · Glomerulosclerosis, Focal Segmental
Primary: Change in Proteinuria at Week 24 From Baseline — 8.42; 7.67 g/g
Phase 1 N=6 Eculizumab Therapy for Dense Deposit Disease and C3 Nephropathy
Dense Deposit Disease · Membranoproliferative Glomerulonephritis
Primary: Number of Patients With Change in Proteinuria or Serum Creatinine Over Treatment Period — 5 Participants
Phase 2 N=7 Tumor Necrosis Factor Inhibition in Focal Segmental Glomerulosclerosis and Treatment Resistant Minimal Change Disease
FSGS · MCD · Focal Segmental Glomerulosclerosis
Primary: Change in Urine MCP1/Cr Levels — 5.57; 2.89 ng/mg
Phase 4 N=16 Idiopathic Focal Segmental Glomerulosclerosis (FSGS) and Treatment With ACTH
Kidney Diseases
Primary: 24 Hour Proteinuria — 3.6; 3.8; 2.2; 3.0 g/day
Phase 3 N=370 A Study of Mycophenolate Mofetil (CellCept) in Management of Patients With Lupus Nephritis.
Lupus Nephritis
Primary: Induction Phase: Number of Patients Showing Treatment Response — 98; 104; 87; 81 participants — p=0.478
Phase 3 N=124 Phase III Study Assessing the Efficacy and Safety of Pegcetacoplan in Patients With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis
C3G · IC-MPGN · C3 Glomerulopathy
Primary: Randomized Controlled Period: Change From Baseline in Log-Transformed Urine Protein-to-Creatinine Ratio (uPCR) at Week 26 — -1.114; 0.029 log (uPCR) — p=<0.0001
Phase 2 N=125 A Study to Evaluate the Safety and Efficacy of Obinutuzumab Compared With Placebo in Participants With Lupus Nephritis (LN)
Lupus Nephritis
Primary: Percentage of Participants Who Achieve Protocol Defined Complete Renal Response (CRR) at Week 52 — 22; 14 Participants — p=0.1145
Phase 2 N=15 Open-Label Phase II Study to Evaluate the Efficacy and Safety of IdeS in Anti-GBM Disease
Anti-Glomerular Basement Membrane Antibody Disease
Primary: Number of Patients With Independent Renal Function at 6 Months — 5; 5; 10 Participants
Phase 3 N=8 Steroid Treatment for Kidney Disease
Nephrosis · Focal Lipoid Glomerulosclerosis
Primary: Remission Status of Patients After Intermittent Oral Dexamethasone Administered Over 48 Weeks — 1; 1; 2; 1 participants — p=0.9074
Phase 2 N=21 Pirfenidone to Treat Kidney Disease (Focal Segmental Glomerulosclerosis)
Fibrosis · Focal Glomerulosclerosis · Kidney Failure
Primary: Decrease in GFR During Treatment Period — -0.45 ml/min/1.73 m2 — p=<0.01
Phase 2 N=45 Phase II Study on Gusperimus in Patients With Refractory Wegener's Granulomatosis
Wegener's Granulomatosis
Primary: Remission of Vasculitis — 95 Percentage of participants
Phase 2 N=46 Study of Safety and Efficacy of LNP023 in Patients With Kidney Disease Caused by Inflammation
IgA Nephropathy
Primary: MCP-Mod Estimates of the Ratio to Baseline of Urine Protein to Creatinine Ratio (UPCR) (g/Mol) - Parts 1 and 2 at Day 90 — 0.85; 0.80; 0.76; 0.69 Ratio to baseline…
Phase 4 N=52 Tacrolimus Versus Prednisolone for the Treatment of Minimal Change Disease
Minimal Change Disease
Primary: Percentage of Participants Achieving Complete Remission From Nephrotic Syndrome at 8 Weeks — 21; 17 Participants — p=0.12
Phase 4 N=63 Acthar for Treatment-Resistant or Treatment-Intolerant Proteinuria
Idiopathic Focal Segmental Glomerulosclerosis
Primary: Number of Participants With Adverse Events — 0; 11; 60 Participants
Phase 3 N=448 Efficacy and Safety of Belimumab in Patients With Active Lupus Nephritis
Lupus Nephritis
Primary: Double-blind Period: Percentage of Participants With Primary Efficacy Renal Response (PERR) at Week 104 — 32.3; 43.0 Percentage of participants — p=0.0311
Phase 2 N=43 Rituximab and Belimumab for Lupus Nephritis
Lupus Nephritis
Primary: Percentage of Participants With At Least One Grade 3 or Higher Infectious Adverse Event By Week 24, Week 48 and Week 96 — 9.1; 4.8; 22.7; 9.5 percentage of participants…